

Anna G Turkina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2369235/publications.pdf>

Version: 2024-02-01

82
papers

1,719
citations

516561

16
h-index

289141

40
g-index

83
all docs

83
docs citations

83
times ranked

1594
citing authors

#	ARTICLE	IF	CITATIONS
1	Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Main Objectives, Design, and Expected Results. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2022, 15, 54-61.	0.1	0
2	National Clinical Guidelines on Diagnosis and Treatment of Ph-Negative Myeloproliferative Neoplasms (Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis) (Edition 2020). <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 262-298.	0.1	15
3	Factors for Sustaining Molecular Remission after Discontinuation of Tyrosine Kinase Inhibitors Therapy in Chronic Myeloid Leukemia: Results of Non-Randomized Prospective Clinical Trial. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 1-12.	0.1	3
4	Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. <i>Leukemia</i> , 2021, 35, 1631-1642.	3.3	18
5	Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7009-7009.	0.8	4
6	Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. <i>Blood</i> , 2021, 138, 2042-2050.	0.6	95
7	A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. <i>Blood</i> , 2021, 138, 2031-2041.	0.6	147
8	Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 118-128.	0.1	1
9	Humoral Immunity and Adverse Events after Vaccination Against COVID-19 By a Vector Based Vaccine Sputnik V in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4599-4599.	0.6	1
10	Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. <i>Blood</i> , 2021, 138, 310-310.	0.6	13
11	Results of a Single Center Survey on Vaccination Against COVID-19 in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4604-4604.	0.6	0
12	PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including <i>BCR::ABL1</i>T315I. <i>Blood</i>, 2021, 138, 1482-1482.</i>	0.6	6
13	The 15 Year Long-Term Survival of Patients with Chronic Myeloid Leukaemia from 35 Regions of Russian Federation: A Follow up of a Multicenter Observation Study Eutos Osp Initiated By European Leukemia NET. <i>Blood</i> , 2021, 138, 5035-5035.	0.6	0
14	The First Results of Asciminib Therapy in Highly Pretreated Chronic Myeloid Leukemia Patients Under the Managed Access Program (MAP) in Russian Federation. <i>Blood</i> , 2021, 138, 1483-1483.	0.6	2
15	Biological Mechanisms of Sustaining Deep Molecular Response in Chronic Myeloid Leukemia Upon Withdrawal of Tyrosine Kinase Inhibitors. <i>Klinicheskaya Onkologematologiya/Clinical Oncohematology</i> , 2021, 14, 427-435.	0.1	0
16	CML-083: Prognostic Factors of Durable Treatment-Free Remission in CML Patients Based on the Prospective Study RU-SKI. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S230.	0.2	0
17	CML-143: BCR-ABL1 Translocation Combined with JAK2 or CALR Mutations in Russian CML Patients Undergoing TKI Therapy: Transcript Level and Mutation Allele Burden. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S235-S236.	0.2	0
18	CML-266: Second Generation Tyrosine Kinase Inhibitors in First Line Can Reduce the Time to Treatment-Free Remission in Chronic Myeloid Leukemia Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S239.	0.2	0

#	ARTICLE	IF	CITATIONS
19	CML-270: Dose De-Escalation of Second-Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Major and Deep Molecular Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S239-S240.	0.2	0
20	Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e328-e335.	0.2	0
21	The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2138-2149.	3.3	55
22	Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 267-271.	0.2	9
23	TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. <i>British Journal of Haematology</i> , 2020, 190, 869-876.	1.2	40
24	ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2020, 136, 29-30.	0.6	3
25	Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in		

#	ARTICLE	IF	CITATIONS
37	Risks and challenges of CML management during pregnancy: Looking for a balanced decision. <i>European Journal of Haematology</i> , 2019, 102, 378-379.	1.1	10
38	Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients. <i>BMC Medical Genomics</i> , 2019, 12, 37.	0.7	4
39	Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database. <i>Blood</i> , 2019, 134, 498-498.	0.6	11
40	PF-114: A 4th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1T315I. <i>Blood</i> , 2019, 134, 1638-1638.	0.6	15
41	ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7005-7005.	0.8	6
42	TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ACCORDING TO THE RUSSIAN PART OF THE EUTOS POPULATION-BASED STUDY. <i>Gematologiya i Transfuziologiya</i> , 2019, 64, 106-121.	0.1	5
43	Treatment-free remission in patients with chronic myeloid leukemia: literature review. <i>Oncogematologiya</i> , 2019, 14, 12-22.	0.1	3
44	On a Long Way to the Treatment Free Remission: The Results of the Long-Term Observation of the Chronic Myeloid Leukemia Patients in Russian Part of EUTOS Population-Based Study. <i>Blood</i> , 2019, 134, 5902-5902.	0.6	0
45	The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial. <i>Blood</i> , 2019, 134, 2925-2925.	0.6	0
46	Changes in the Multipotent Stromal Mesenchymal Cells from the Bone Marrow of the Patients with Hematological Diseases in Debut and after the Treatment. <i>Blood</i> , 2019, 134, 5014-5014.	0.6	0
47	CHANGES IN STROMAL PROGENITOR CELLS DERIVED FROM BONE MARROW IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA AT THE ONSET OF THE DISEASE AND DURING TREATMENT. <i>Gematologiya i Transfuziologiya</i> , 2019, 64, 424-435.	0.1	1
48	Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase. <i>Annals of Internal Medicine</i> , 2018, 168, 461.	2.0	105
49	Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation. <i>Leukemia and Lymphoma</i> , 2018, 59, 2512-2515.	0.6	1
50	Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. <i>Leukemia and Lymphoma</i> , 2018, 59, 733-738.	0.6	29
51	ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S222.	0.2	3
52	Treatment of Patients with Chronic Myeloid Leukemia During Pregnancy According to Scheme Considering the Leukemic Burden and Term of Pregnancy (the LRT Scheme). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S227-S228.	0.2	2
53	Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Interim Results of Russian Prospective Multicenter Trial RU-SKI. <i>Blood</i> , 2018, 132, 3023-3023.	0.6	1
54	Chronic Myeloid Leukemia Diagnosed during Pregnancy: Therapy, Outcomes and Follow-up. <i>Blood</i> , 2018, 132, 4255-4255.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy. <i>Blood</i> , 2018, 132, 4254-4254.	0.6	6
56	Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy. <i>Blood</i> , 2018, 132, 790-790.	0.6	13
57	Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7003-7003.	0.8	4
58	Analysis of the Effectiveness of Maintenance Therapy By Imatinib in Patients with Pdgfra-Positive Neoplasm. <i>Blood</i> , 2018, 132, 1755-1755.	0.6	0
59	Prognostic Model of Successful Tyrosine Kinase Inhibitors Discontinuation Based on the Russian RU-SKI Multicenter Prospective Study. <i>Blood</i> , 2018, 132, 1740-1740.	0.6	0
60	Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1735-1735.	0.6	1
61	Nilotinib dose optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. <i>British Journal of Haematology</i> , 2017, 179, 219-228.	1.2	14
62	Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018027.	0.5	21
63	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , 2017, 130, 900-900.	0.6	9
64	Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia. <i>PLoS ONE</i> , 2017, 12, e0182901.	1.1	7
65	GROUP OF AUTHORS UNDER THE SUPERVISION OF ACADEMICIAN VG SAVCHENKO. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2017, 10, 294-316.	0.1	19
66	Clinical features and outcomes in chronic myeloid leukemia with T315I mutation. <i>Cellular Therapy and Transplantation</i> , 2017, 6, 26-35.	0.2	1
67	PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy. <i>Blood</i> , 2017, 130, 895-895.	0.6	4
68	The ability of multipotent mesenchymal stromal cells from the bone marrow of patients with leukemia to maintain normal hematopoietic progenitor cells. <i>European Journal of Haematology</i> , 2016, 97, 245-252.	1.1	8
69	Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia. <i>BMC Genetics</i> , 2016, 17, 14.	2.7	12
70	Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 1669-1676.	0.6	16
71	Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2016, 128, 1891-1891.	0.6	9
72	Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. <i>Blood</i> , 2016, 128, 792-792.	0.6	16

#	ARTICLE	IF	CITATIONS
73	Copy Number Variations in Cytochromes and Glutathione-Transferases As Early Predictors of the Efficacy of Tyrosine Kinase Inhibitors in CML. <i>Blood</i> , 2016, 128, 5457-5457.	0.6	0
74	Impact of Simultaneous Presence of Additional Chromosome Aberrations and BCR-ABL1 Kinase Domain Mutations on Survival in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 5437-5437.	0.6	0
75	Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2015, 90, 755-768.	2.0	72
76	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	2.0	102
77	Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. <i>Leukemia and Lymphoma</i> , 2012, 53, 907-914.	0.6	30
78	Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1016-1026.	1.7	2
79	Expanding Nilotinib Access in Clinical Trials (ENACT). <i>Cancer</i> , 2012, 118, 118-126.	2.0	61
80	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood</i> , 2011, 118, 4567-4576.	0.6	406
81	Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 7697-7702.	0.8	199
82	Fluorescence In Situ Hybridization Studies of Interphase Nuclei for Assessing Response to Therapy in Patients with Chronic Myeloid Leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1998, 106, 128-134.	1.0	9